ASH 2022 | The challenges associated with transfusion dependence in patients with MF
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, shares some insights into the burden of transfusion dependence in patients with myelofibrosis (MF), highlighting the fiscal cost of transfusions, scarcity of blood, and the association between transfusions and increased risk of adverse events (AEs). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kratos Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Imago BioSciences: Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Accurate Pharmaceuticals: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Morphosys/Constellation: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; PharmaEssentia: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
